Company news

Moderna, Inc. news in 2022

Moderna, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Moderna Announces its COVID-19 Vaccine Phase 2/3 Study in Children 6 Months to Under 6 Years Has Successfully Met Its Primary Endpoint

March 22, 2022

Moderna Announces New Development Programs Ahead of 3rd Annual Vaccines Day

March 21, 2022

Moderna Announces New Supply Agreement for 2023 with Switzerland for Additional Seven Million Doses of Moderna's COVID-19 Booster Vaccine

March 20, 2022

Moderna Submits Amendment to the Emergency Use Authorization for an Additional Booster Dose of its COVID-19 Vaccine in the U.S.

March 16, 2022

Moderna and the Japanese Government Reach an Agreement to Supply Japan with Additional 70 Million Doses of Moderna's COVID-19 Booster Vaccine

March 15, 2022

Moderna Announces First Participant Dosed in Phase 1 Study of its HIV Trimer mRNA Vaccine

March 13, 2022

Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Bivalent Booster Candidate

March 9, 2022

Moderna Announces Its Global Public Health Strategy

March 6, 2022

Moderna Announces Establishment of Enterprise Solutions Hub in Atlanta, Georgia

March 2, 2022

Moderna Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Updates

February 23, 2022

Moderna and Thermo Fisher Scientific Announce Long-Term Strategic Collaboration

February 22, 2022

Moderna Initiates Phase 3 Portion of Pivotal Trial for mRNA Respiratory Syncytial Virus (RSV) Vaccine Candidate, Following Independent Safety Review of Interim Data

February 21, 2022

Moderna Expands Its mRNA Pipeline with Three New Development Programs

February 17, 2022

Therapeutic Goods Administration of Australia Authorizes Moderna's Covid-19 Vaccine in Children (6-11 Years)

February 15, 2022

Moderna Announces Plan to Expand Footprint in Asia with Four Additional Subsidiaries

February 14, 2022

Moderna Announces New Supply Agreement with Colombia for Additional 10.8 Million Doses of Moderna's COVID-19 Vaccine

February 7, 2022

Moderna to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022

February 2, 2022

Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine Spikevax

January 30, 2022

Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Booster Candidate and Publication of Data on Booster Durability Against Omicron Variant

January 25, 2022

Moderna Announces Advances Across Its Industry-Leading mRNA Pipeline and Provides Business Update

January 9, 2022

Moderna Announces First Participant Dosed in Phase 1 Study of its mRNA Epstein-Barr Virus (EBV) Vaccine

January 4, 2022

← Newer news releases

Calls in 2022

Decks in 2022